EX-99.1 2 nxgn-ex991_7.htm EX-99.1 nxgn-ex991_7.htm

Exhibit 99.1

 

 

 

 

 

 

FOR IMMEDIATE RELEASE

May 28, 2019

 

NextGen Healthcare, Inc. Reports Fiscal 2019 Fourth Quarter and Year-End Results

IRVINE, Calif. – (BUSINESS WIRE) – NextGen Healthcare, Inc. (NASDAQ: NXGN), a leading provider of ambulatory-focused healthcare technology solutions, announced today its fiscal 2019 fourth quarter and year end March 31, 2019 operating results.

 

"The hallmarks of our FY’19 performance were: 1) significant bookings growth and deal-size growth, 2) Best-in-KLAS industry recognition for our practice management solution, 3) the launch of our integrated ambulatory care platform at our User Group Meeting, and 4) continued growth in client satisfaction,” commented Rusty Frantz, president and chief executive officer of NextGen Healthcare. “While we encountered some market headwinds in the second half that impacted top line revenue performance, we’re pleased to deliver EPS at the high end of our FY19 range. We remain confident in our growth strategy, the market opportunity, and our plan to deliver 20% operating margin in the next three years.”

 

Fiscal 2019 Fourth Quarter and Year-End Highlights

As a result of the adoption of Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”), the GAAP comparisons below compare fourth quarter and fiscal year 2019 results under ASC 606 to the fourth quarter and fiscal year 2018 results under the legacy revenue guidance (“ASC 605”). A reconciliation of fourth quarter and fiscal year results for fiscal 2019 from ASC 606 to ASC 605 can be found in the tables at the end of the press release.

 

On a GAAP basis, revenue for the fiscal 2019 fourth quarter was $134.8 million compared to $135.8 million a year-ago. On a pro forma basis under ASC 605, revenue for the fiscal 2019 fourth quarter was $134.3 million. 

 

On a GAAP basis, net income for the fiscal 2019 fourth quarter was $3.9 million, compared with net loss of $11.0 million in the fiscal 2018 fourth quarter. On a pro forma basis under ASC 605, net income for the fiscal 2019 fourth quarter was $1.3 million.

 

On a GAAP basis, fully diluted net income per share was $0.06 in the fiscal 2019 fourth quarter compared to a loss of $0.17 per share for the same period a year ago. On a non-GAAP basis, fully diluted earnings per share for the fiscal 2019 fourth quarter was $0.23 versus $0.16 reported in the fourth quarter a year ago. On a pro forma non-GAAP basis, under ASC 605, fully diluted earnings per share for the fiscal 2019 fourth quarter was $0.19.

 

For the fiscal year ended March 31, 2019, revenue on a GAAP basis was $529.2 million compared to $531.0 million a year-ago. On a pro forma basis under ASC 605, revenue for the fiscal year 2019 was $527.3 million. 

 

On a GAAP basis, net income for the fiscal year 2019 was $24.5 million, compared with net income of $2.4 million in fiscal year 2018. On a pro forma basis under ASC 605, net income for the fiscal year 2019 was $17.7 million.


 

On a GAAP basis, fully diluted net income per share was $0.38 in the fiscal year 2019 compared to earnings of $0.04 per share for the same period a year ago.  On a non-GAAP basis, fully diluted earnings per share for the fiscal year 2019 was $0.86 versus $0.70 reported a year ago. On a pro forma non-GAAP basis, under ASC 605, fully diluted earnings per share for the fiscal year 2019 was $0.76.

 

Fiscal 2020 Financial Outlook

The company is providing initial outlook for fiscal 2020 and expects:

 

Revenue of between $543 million and $559 million

 

Non-GAAP EPS of between $0.86 and $0.94

 

Conference Call Information

NextGen Healthcare will host a conference call to discuss its fiscal 2019 fourth quarter and year-end results on Tuesday, May 28, 2019 at 5:00 PM ET (2:00 PM PT). Shareholders and interested participants may listen to a live broadcast of the conference call by dialing 866-750-8947 or 720-405-1352 for international callers, and referencing participant code 9175604 approximately 15 minutes prior to the call. A live webcast of the conference call will be available on the investor relations section of the company’s web site and an audio file of the call will also be archived for 90 days at investor.nextgen.com. After the conference call, a replay will be available until June 4, 2019 and can be accessed by dialing 800-585-8367 or 404-537-3406 for international callers, and referencing participant code 9175604.

 

2019 Annual Shareholders' Meeting

In addition, NextGen Healthcare will hold its 2019 Annual Shareholders' Meeting on Thursday, August 15, 2019 at 9:00 a.m. Pacific time. The meeting will be held at the Marriott Hotel, 18000 Von Karman Avenue, Irvine, California 92612. Shareholders of record as of June 17, 2019 are eligible to vote and attend. Proxy materials and the 2019 Annual Report will be made available to shareholders of record and will also be posted on the Company's website.

 

About NextGen Healthcare, Inc

NextGen Healthcare is enabling the transformation of ambulatory care by providing a range of software, services, and analytics solutions to medical and dental group practices. The company's portfolio delivers foundational capabilities to empower physician success, enrich the patient care experience, and enable the transition to value-based healthcare. Visit www.nextgen.com for additional information.

 

Media Contact:
NextGen Healthcare
Cynthia Ragland, (949) 255-2600 x75416
cragland@nextgen.com

or

Investor Contact:

Westwicke Partners

Bob East or Asher Dewhurst

Westwicke Partners

443-213-0500

 

 


SAFE HARBOR PROVISIONS FOR FORWARD-LOOKING STATEMENTS

This news release may contain forward-looking statements within the meaning of the federal securities laws, including but not limited to, statements regarding future events, developments in the healthcare sector and regulatory framework, the Company's future performance, as well as management's expectations, beliefs, intentions, plans, estimates or projections relating to the future (including, without limitation, statements concerning revenue, net income, and earnings per share). Risks and uncertainties exist that may cause the results to differ materially from those set forth in these forward-looking statements. Factors that could cause the anticipated results to differ from those described in the forward-looking statements and additional risks and uncertainties are set forth in Part I, Item A of our most recent Annual Report on Form 10-K and subsequently filed Quarterly Reports on Form 10-Q, including but not limited to: the volume and timing of systems sales and installations; length of sales cycles and the installation process; the possibility that products will not achieve or sustain market acceptance; seasonal patterns of sales and customer buying behavior; impact of incentive payments under The American Recovery and Reinvestment Act on sales and the ability of the Company to meet continued certification requirements; uncertainties related to the future impact of U.S. tax reform; the impact of governmental and regulatory agency investigations; the development by competitors of new or superior technologies; the timing, cost and success or failure of new product and service introductions, development and product upgrade releases; undetected errors or bugs in software; product liability; changing economic, political or regulatory influences in the health-care industry; changes in product-pricing policies; availability of third-party products and components; competitive pressures including product offerings, pricing and promotional activities; the Company's ability or inability to attract and retain qualified personnel; possible regulation of the Company's software by the U.S. Food and Drug Administration; changes of accounting estimates and assumptions used to prepare the prior periods' financial statements; disruptions caused by acquisitions of companies, products, or technologies; and general economic conditions. A significant portion of the Company's quarterly sales of software product licenses and computer hardware is concluded in the last month of a fiscal quarter, generally with a concentration of such revenues earned in the final ten business days of that month. Due to these and other factors, the Company's revenues and operating results are very difficult to forecast. A major portion of the Company's costs and expenses, such as personnel and facilities, are of a fixed nature and, accordingly, a shortfall or decline in quarterly and/or annual revenues typically results in lower profitability or losses. As a result, comparison of the Company's period-to-period financial performance is not necessarily meaningful and should not be relied upon as an indicator of future performance. These forward-looking statements speak only as of the date hereof. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.

 

USE OF NON-GAAP FINANCIAL MEASURES

This news release contains certain non-GAAP (Generally Accepted Accounting Principles) financial measures, which are provided only as supplemental information. Investors should consider these non-GAAP financial measures only in conjunction with the comparable GAAP financial measures. These non-GAAP measures are not in accordance with or a substitute for U.S. GAAP. Pursuant to the requirements of Regulation G, the Company has provided a reconciliation of non-GAAP financial measures to the most directly comparable financial measure in the accompanying financial tables. Other companies may calculate non-GAAP measures differently than NextGen Healthcare, Inc., which limits comparability between companies. The Company believes that its presentation of non-GAAP diluted earnings per share provides useful supplemental information to investors and management regarding the Company's financial condition and results. The presentation of non-GAAP financial information is not intended to be considered in isolation or as a substitute for, or superior to, financial information prepared and presented in accordance with GAAP. The Company calculates non-GAAP diluted earnings per share by excluding net acquisition costs, amortization of acquired intangible assets, amortization of deferred debt issuance costs, restructuring costs, net securities litigation defense costs and settlement, share-based compensation, impairment of assets, and other non-run-rate expenses from GAAP income before provision for income taxes. The Company


utilizes a normalized non-GAAP tax rate to provide better consistency across the interim reporting periods within a given fiscal year by eliminating the effects of non-recurring and period-specific items, which can vary in size and frequency, and which are not necessarily reflective of the Company’s longer-term operations.

 

The normalized non-GAAP tax rate applied to fiscal year 2019 was 22.0%, compared to 30.5% for fiscal year 2018, which was updated as a result of the enactment of the new tax reform legislation on December 22, 2017. The determination of this rate is based on the consideration of both historic and projected financial results. The Company may adjust its non-GAAP tax rate as additional information becomes available and in conjunction with any other significant events occur that may materially affect this rate, such as merger and acquisition activity, changes in business outlook, or other changes in expectations regarding tax regulations.

 

The Company’s future period guidance in this release includes adjustments for items not indicative of the Company’s core operations. Such adjustments are generally expected to be of a nature similar to those adjustments applied to the Company’s historic GAAP financial results in the determination of the Company’s non-GAAP diluted earnings per share. Such adjustments, however, may be affected by changes in ongoing assumptions and judgments as to the items that are excluded in the calculation of non-GAAP adjusted net income and adjusted diluted earnings per share, as described in this release. The exact amount and probable significance of these adjustments, including net acquisition costs, net securities litigation defense costs, and other non-run-rate expenses, are not currently determinable without unreasonable efforts, but may be significant. These items cannot be reliably quantified or forecasted due to the combination of their historic and expected variability. It is therefore not practicable to reconcile this non-GAAP guidance to the most comparable GAAP measures.

 

 

 


NEXTGEN HEALTHCARE, INC.

CONSOLIDATED STATEMENTS OF INCOME

(In thousands, except per share data)

(Unaudited)

 

 

Three Months Ended March 31,

 

 

Fiscal Year Ended March 31,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

$

120,151

 

 

$

118,598

 

 

$

473,921

 

 

$

476,214

 

Software, hardware, and other non-recurring

 

14,634

 

 

 

17,177

 

 

 

55,252

 

 

 

54,805

 

Total revenues

 

134,785

 

 

 

135,775

 

 

 

529,173

 

 

 

531,019

 

Cost of revenue:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Recurring

 

48,174

 

 

 

48,856

 

 

 

191,496

 

 

 

194,360

 

Software, hardware, and other non-recurring

 

5,959

 

 

 

6,775

 

 

 

26,711

 

 

 

25,085

 

Amortization of capitalized software costs and acquired intangible assets

 

7,924

 

 

 

6,346

 

 

 

28,490

 

 

 

22,090

 

Total cost of revenue

 

62,057

 

 

 

61,977

 

 

 

246,697

 

 

 

241,535

 

Gross profit

 

72,728

 

 

 

73,798

 

 

 

282,476

 

 

 

289,484

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

44,710

 

 

 

65,709

 

 

 

164,879

 

 

 

193,226

 

Research and development costs, net

 

19,813

 

 

 

21,098

 

 

 

80,994

 

 

 

81,259

 

Amortization of acquired intangible assets

 

1,028

 

 

 

1,795

 

 

 

4,344

 

 

 

7,810

 

Impairment of assets

 

 

 

 

3,757

 

 

 

 

 

 

3,757

 

Restructuring costs

 

640

 

 

 

481

 

 

 

640

 

 

 

611

 

Total operating expenses

 

66,191

 

 

 

92,840

 

 

 

250,857

 

 

 

286,663

 

Income (loss) from operations

 

6,537

 

 

 

(19,042

)

 

 

31,619

 

 

 

2,821

 

Interest income

 

103

 

 

 

19

 

 

 

216

 

 

 

55

 

Interest expense

 

(595

)

 

 

(1,073

)

 

 

(2,814

)

 

 

(3,323

)

Other income (expense), net

 

(117

)

 

 

85

 

 

 

267

 

 

 

37

 

Income (loss) before provision for (benefit of) income taxes

 

5,928

 

 

 

(20,011

)

 

 

29,288

 

 

 

(410

)

Provision for (benefit of) income taxes

 

2,000

 

 

 

(8,964

)

 

 

4,794

 

 

 

(2,830

)

Net income (loss)

$

3,928

 

 

$

(11,047

)

 

$

24,494

 

 

$

2,420

 

Net income (loss) per share:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

$

0.06

 

 

$

(0.17

)

 

$

0.38

 

 

$

0.04

 

Diluted

$

0.06

 

 

$

(0.17

)

 

$

0.38

 

 

$

0.04

 

Weighted-average shares outstanding:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Basic

 

64,749

 

 

 

63,888

 

 

 

64,417

 

 

 

63,435

 

Diluted

 

64,917

 

 

 

63,888

 

 

 

64,600

 

 

 

63,440

 

 



NEXTGEN HEALTHCARE, INC.

CONSOLIDATED BALANCE SHEETS

(In thousands, except per share data)

(Unaudited)

 

 

 

March 31, 2019

 

 

March 31, 2018

 

ASSETS

 

 

 

 

 

 

 

 

Current assets:

 

 

 

 

 

 

 

 

Cash and cash equivalents

 

$

33,079

 

 

$

28,845

 

Restricted cash and cash equivalents

 

 

1,443

 

 

 

2,373

 

Accounts receivable, net

 

 

87,459

 

 

 

84,962

 

Contract assets

 

 

13,242

 

 

 

 

Inventory

 

 

120

 

 

 

180

 

Income taxes receivable

 

 

3,682

 

 

 

8,122

 

Prepaid expenses and other current assets

 

 

20,826

 

 

 

17,180

 

Total current assets

 

 

159,851

 

 

 

141,662

 

Equipment and improvements, net

 

 

21,404

 

 

 

26,795

 

Capitalized software costs, net

 

 

37,855

 

 

 

26,318

 

Deferred income taxes, net

 

 

6,194

 

 

 

9,219

 

Contract assets, net of current

 

 

3,747

 

 

 

 

Intangibles, net

 

 

52,595

 

 

 

74,091

 

Goodwill

 

 

218,771

 

 

 

218,875

 

Other assets

 

 

32,478

 

 

 

18,795

 

Total assets

 

$

532,895

 

 

$

515,755

 

LIABILITIES AND SHAREHOLDERS' EQUITY

 

 

 

 

 

 

 

 

Current liabilities:

 

 

 

 

 

 

 

 

Accounts payable

 

$

5,432

 

 

$

4,213

 

Contract liabilities

 

 

56,009

 

 

 

54,079

 

Accrued compensation and related benefits

 

 

25,663

 

 

 

27,910

 

Income taxes payable

 

 

64

 

 

 

73

 

Other current liabilities

 

 

41,064

 

 

 

48,317

 

Total current liabilities

 

 

128,232

 

 

 

134,592

 

Contract liabilities, net of current

 

 

 

 

 

1,173

 

Deferred compensation

 

 

5,905

 

 

 

6,086

 

Line of credit

 

 

11,000

 

 

 

37,000

 

Other noncurrent liabilities

 

 

11,812

 

 

 

13,494

 

Total liabilities

 

 

156,949

 

 

 

192,345

 

Commitments and contingencies

 

 

 

 

 

 

 

 

Shareholders' equity:

 

 

 

 

 

 

 

 

Common stock

 

 

 

 

 

 

 

 

$0.01 par value; authorized 100,000 shares; issued and outstanding 64,838 and 63,995 shares at March 31, 2019 and March 31, 2018, respectively

 

 

648

 

 

 

640

 

Additional paid-in capital

 

 

264,908

 

 

 

244,462

 

Accumulated other comprehensive loss

 

 

(1,231

)

 

 

(400

)

Retained earnings (1)

 

 

111,621

 

 

 

78,708

 

Total shareholders' equity

 

 

375,946

 

 

 

323,410

 

Total liabilities and shareholders' equity

 

$

532,895

 

 

$

515,755

 

 

 

(1)

Includes cumulative effect adjustment related to the adoption of ASC 606.

 



NEXTGEN HEALTHCARE, INC.

NON-GAAP FINANCIAL MEASURES

(In thousands, except per share data)

 

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE

 

 

Three Months Ended March 31,

 

 

Fiscal Year Ended March 31,

 

 

2019

 

 

2018

 

 

2019

 

 

2018

 

Income before provision for income taxes - GAAP

$

5,928

 

 

$

(20,011

)

 

$

29,288

 

 

$

(410

)

Non-GAAP adjustments:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Acquisition costs, net

 

1,010

 

 

 

339

 

 

 

3,068

 

 

 

1,908

 

Amortization of acquired intangible assets

 

5,316

 

 

 

6,029

 

 

 

21,496

 

 

 

23,380

 

Amortization of deferred debt issuance costs

 

178

 

 

 

803

 

 

 

710

 

 

 

1,610

 

Restructuring costs

 

640

 

 

 

481

 

 

 

640

 

 

 

611

 

Securities litigation defense costs and settlement, net of insurance

 

202

 

 

 

19,984

 

 

 

(5,205

)

 

 

20,700

 

Share-based compensation

 

4,153

 

 

 

3,611

 

 

 

16,102

 

 

 

12,196

 

Impairment of assets

 

 

 

 

3,757

 

 

 

 

 

 

3,757

 

Other non-run-rate expenses*

 

1,492

 

 

 

 

 

 

5,471

 

 

 

263

 

Total adjustments to GAAP income before provision for income taxes:

 

12,991

 

 

 

35,004

 

 

 

42,282

 

 

 

64,425

 

Income before provision for income taxes - Non-GAAP

 

18,919

 

 

 

14,993

 

 

 

71,570

 

 

 

64,015

 

Provision for income taxes

 

4,161

 

 

 

4,573

 

 

 

15,745

 

 

 

19,525

 

Net income - Non-GAAP

$

14,758

 

 

$

10,420

 

 

$

55,825

 

 

$

44,490

 

Diluted net income per share - Non-GAAP

$

0.23

 

 

$

0.16

 

 

$

0.86

 

 

$

0.70

 

Weighted-average shares outstanding (diluted):

 

64,917

 

 

 

63,888

 

 

 

64,600

 

 

 

63,440

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

RECONCILIATION OF NON-GAAP DILUTED EARNINGS PER SHARE UNDER ASC 605

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Income before provision for income taxes - Non-GAAP

 

18,919

 

 

 

 

 

 

 

71,570

 

 

 

 

 

Adjustments due to adoption of ASC 606

 

(3,100

)

 

 

 

 

 

 

(8,799

)

 

 

 

 

Income before provision for income taxes - Non-GAAP under ASC 605

 

15,819

 

 

 

 

 

 

 

62,771

 

 

 

 

 

Provision for income taxes

 

3,481

 

 

 

 

 

 

 

13,810

 

 

 

 

 

Net income - Non-GAAP under ASC 605

$

12,338

 

 

 

 

 

 

$

48,961

 

 

 

 

 

Diluted net income per share - Non-GAAP under ASC 605

$

0.19

 

 

 

 

 

 

$

0.76

 

 

 

 

 

Weighted-average shares outstanding (diluted):

 

64,917

 

 

 

 

 

 

 

64,600

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

* Other non-run-rate expenses consist primarily of severance and other employee-related costs and professional services costs not related to core operations.

 

 

 

 

 

 

 

 

 

 

 

 

 

 


We adopted Accounting Standards Update No. 2014-09, Revenue from Contracts with Customers: Topic 606 (“ASC 606”) and all related amendments as of April 1, 2018 using the modified retrospective method for all contracts not completed as of the date of adoption. Results for reporting periods beginning after April 1, 2018 are presented under ASC 606, while prior period comparative information has not been adjusted and continue to be reported under the accounting standards in effect for those prior periods.

The impact of the adoption of ASC 606 on our consolidated statements of net income for the three months and fiscal year ended March 31, 2019, assuming that the previous revenue recognition guidance had been in effect, is summarized as follows:

 

 

 

 

Three Months Ended March 31, 2019

 

 

 

As reported under

 

 

Adjustments due to

 

 

As disclosed under

 

 

 

ASC 606

 

 

adoption of ASC 606

 

 

ASC 605

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Subscription services

 

$

29,884

 

 

$

(2,039

)

 

$

27,845

 

Support and maintenance

 

 

40,242

 

 

 

(1,473

)

 

 

38,769

 

Managed services

 

 

24,155

 

 

 

3,770

 

 

 

27,925

 

Electronic data interchange and data services

 

 

25,870

 

 

 

(25

)

 

 

25,845

 

Total recurring revenues

 

 

120,151

 

 

 

233

 

 

 

120,384

 

Software license and hardware

 

 

9,109

 

 

 

(662

)

 

 

8,447

 

Other non-recurring services

 

 

5,525

 

 

 

(82

)

 

 

5,443

 

Total software, hardware, and other non-recurring revenues

 

 

14,634

 

 

 

(744

)

 

 

13,890

 

Total revenue

 

 

134,785

 

 

 

(511

)

 

 

134,274

 

Total cost of revenue

 

 

62,057

 

 

 

30

 

 

 

62,087

 

Gross profit

 

 

72,728

 

 

 

(541

)

 

 

72,187

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

44,710

 

 

 

2,559

 

 

 

47,269

 

Research and development costs, net

 

 

19,813

 

 

 

 

 

 

19,813

 

Amortization of acquired intangibles

 

 

1,028

 

 

 

 

 

 

1,028

 

Restructuring costs

 

 

640

 

 

 

 

 

 

640

 

Total operating expenses

 

 

66,191

 

 

 

2,559

 

 

 

68,750

 

Income from operations

 

 

6,537

 

 

 

(3,100

)

 

 

3,437

 

Interest and other income, net

 

 

(609

)

 

 

 

 

 

(609

)

Income before provision for income taxes

 

 

5,928

 

 

 

(3,100

)

 

 

2,828

 

Provision for income taxes

 

 

2,000

 

 

 

(432

)

 

 

1,568

 

Net income

 

$

3,928

 

 

$

(2,668

)

 

$

1,260

 

 


 

 

Fiscal Year Ended March 31, 2019

 

 

 

As reported under

 

 

Adjustments due to

 

 

As disclosed under

 

 

 

ASC 606

 

 

adoption of ASC 606

 

 

ASC 605

 

Revenues:

 

 

 

 

 

 

 

 

 

 

 

 

Subscription services

 

$

117,502

 

 

$

(7,548

)

 

$

109,954

 

Support and maintenance

 

 

160,798

 

 

 

(5,262

)

 

 

155,536

 

Managed services

 

 

98,203

 

 

 

12,516

 

 

 

110,719

 

Electronic data interchange and data services

 

 

97,418

 

 

 

(136

)

 

 

97,282

 

Total recurring revenues

 

 

473,921

 

 

 

(430

)

 

 

473,491

 

Software license and hardware

 

 

35,122

 

 

 

(1,830

)

 

 

33,292

 

Other non-recurring services

 

 

20,130

 

 

 

382

 

 

 

20,512

 

Total software, hardware, and other non-recurring revenues

 

 

55,252

 

 

 

(1,448

)

 

 

53,804

 

Total revenue

 

 

529,173

 

 

 

(1,878

)

 

 

527,295

 

Total cost of revenue

 

 

246,697

 

 

 

159

 

 

 

246,856

 

Gross profit

 

 

282,476

 

 

 

(2,037

)

 

 

280,439

 

Operating expenses:

 

 

 

 

 

 

 

 

 

 

 

 

Selling, general and administrative

 

 

164,879

 

 

 

6,762

 

 

 

171,641

 

Research and development costs, net

 

 

80,994

 

 

 

 

 

 

80,994

 

Amortization of acquired intangibles

 

 

4,344

 

 

 

 

 

 

4,344

 

Restructuring costs

 

 

640

 

 

 

 

 

 

640

 

Total operating expenses

 

 

250,857

 

 

 

6,762

 

 

 

257,619

 

Income from operations

 

 

31,619

 

 

 

(8,799

)

 

 

22,820

 

Interest and other income, net

 

 

(2,331

)

 

 

 

 

 

(2,331

)

Income before provision for income taxes

 

 

29,288

 

 

 

(8,799

)

 

 

20,489

 

Provision for income taxes

 

 

4,794

 

 

 

(1,982

)

 

 

2,812

 

Net income

 

$

24,494

 

 

$

(6,817

)

 

$

17,677